Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clear Cell Renal Cancer Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer
Interventions
Pazopanib, Temsirolimus, Quality of Life Assessment, Benadryl
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced May 21, 2026, 7:18 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
Pazopanib, Bevacizumab, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced May 21, 2026, 7:18 PM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Axitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cancer, Von Hippel Lindau
Interventions
ZACTIMA (Vandetanib) (ZD6474)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced May 21, 2026, 7:18 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clear Cell Carcinoma, Phase 1, Growth Factor
Interventions
Lymphodepleting chemotherapy, Dexamethasone, Fludarabine, Cyclophosphamate, TGFBR-2 KO CD70 CAR NK
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Renal Cancer, Melanoma
Interventions
Aldesleukin, Sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
1,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1002
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 7:18 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions
Abemaciclib, Cabozantinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Decitabine, Interferon Alfa-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2011 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
IL-2, ATRA
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
IMO-2055
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced May 21, 2026, 7:18 PM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Iodine (124I) Girentuximab
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Burlington, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced May 21, 2026, 7:18 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:18 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions
Casdatifan, Cabozantinib, Placebo
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
40
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
Interventions
MEDI0680, Durvalumab, Nivolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Tampa, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced May 21, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
ATN-161
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
4
States / cities
Irvine, California • San Francisco, California • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced May 21, 2026, 7:18 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Nephrectomy
Drug · Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced May 21, 2026, 7:18 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cyclophosphamide, Fludarabine, LNK001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab, SAbR
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced May 21, 2026, 7:18 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, denileukin diftitox
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced May 21, 2026, 7:18 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Belzutifan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced May 21, 2026, 7:18 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Lenvatinib, Lenvatinib Mesylate, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 7:18 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
Drug · Radiation · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced May 21, 2026, 7:18 PM EDT